G-5 (drug)

Last updated
G-5
3,4-Norbornyl-2,5-dimethoxyamphetamine.svg
Clinical data
Other namesG5; Ganesha-5; GANESHA-5; 3C-G-5; 3,4-Norbornyl-2,5-dimethoxyamphetamine; 3,6-Dimethoxy-4-(2-aminopropyl)benzonorbornane; DOG-5
Routes of
administration 		Oral [1]
Drug class Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Onset of action Very slow [1]
Duration of action 16–30 hours [1]
Identifiers
  • 1-(3,6-dimethoxy-4-tricyclo[6.2.1.02,7]undeca-2,4,6-trienyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C16H23NO2
Molar mass 261.365 g·mol−1
3D model (JSmol)
  • CC(CC1=CC(=C2C3CCC(C3)C2=C1OC)OC)N
  • InChI=1S/C16H23NO2/c1-9(17)6-12-8-13(18-2)14-10-4-5-11(7-10)15(14)16(12)19-3/h8-11H,4-7,17H2,1-3H3
  • Key:MZFVFTFFHRCTIO-UHFFFAOYSA-N

G-5, also known as 3,4-norbornyl-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. [1] [2] [3] It is one of several homologues of Ganesha (G). [1] [2] [3] In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists G-5's dose as 14 to 20 mg orally and its duration as 16 to 30 hours. [1] [2] [3] It is said to have a very slow onset. [1] The effects of G-5 were reported to include an unexpected absence of visual and related sensory activity, excellent mental activity, "absence of the bells and whistles that are expected with a psychedelic in full bloom", mental integration, and little or no body load. [1] Per Shulgin, it was somehow lacking in characteristics that would've made it fully favorable, perhaps the lack of perceptual effects, which resulted in there being little drive to further explore it. [1] The drug is not a monoamine releasing agent of either serotonin or dopamine. [4] The chemical synthesis of G-5 has been described. [1] G-5 was first described in the literature by Shulgin and colleagues in 1991. [1] [4]

Contents

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628. https://erowid.org/library/books_online/pihkal/pihkal084.shtml
  2. 1 2 3 Jacob P, Shulgin AT (1994). "Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs". In Lin GC, Glennon RA (eds.). Hallucinogens: An Update (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 146. National Institute on Drug Abuse. pp. 74–91. PMID   8742795. Archived from the original on 13 July 2025.
  3. 1 2 3 Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN   978-0-12-433951-4. Archived from the original on 13 July 2025.
  4. 1 2 McKenna DJ, Guan XM, Shulgin AT (March 1991). "3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine". Pharmacol Biochem Behav. 38 (3): 505–512. doi:10.1016/0091-3057(91)90005-m. PMID   1829838.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.